JPMorgan Still Sees Moderna Overvalued Despite Raising Its Target
JPMorgan raised its price target for Moderna (MRNA) from $77 to $102 but maintained an Underweight rating, citing overvaluation. The increase follows Moderna's updated guidance and new expense framework, with key events expected in late 2026 or early 2027. JPMorgan notes a disconnect between Moderna's market value and its pipeline potential.
How this was made
The 30-second read
Why it matters
For trading, the key tension is higher upside framing (PT raised) versus persistent valuation caution (Underweight), with the next major event pegged to interim Phase II results for intismeran in late 2026 or early 2027.
Market read
A large-cap biotech analyst note can move positioning quickly, but the maintained Underweight suggests valuation risk remains the dominant debate.
What to watch
The note highlights a 2027 expense framework and cash balance; traders may focus more on cost trajectory and liquidity than on the pipeline valuation math.
Background
The piece ties JPMorgan’s target increase to Moderna’s analyst day, updated 2026 guidance, and a new expense framework extending into 2027 and beyond.
Ticker impact
JPMorgan raised Moderna’s price target to $102 but kept an Underweight rating, citing valuation disconnect versus the intismeran pipeline.
Likely choppy trading, with support from the higher target offset by continued Underweight positioning and valuation skepticism.
The article combines a bullish PT revision with a bearish rating and explicit valuation rationale tied to pipeline support and next clinical catalyst timing.
Market effects
Biotech sentiment may tilt modestly toward oncology-focused platforms as expense guidance and Phase III momentum get re-framed.
Primarily US biotech/healthcare sentiment via a large-cap name’s analyst note.
Limited, as the catalyst is company-specific clinical timing and US analyst positioning.
Counterpoint
The Underweight call may be overly valuation-centric if intismeran’s next Phase II interim readout de-risks the pipeline faster than JPMorgan assumes.
Key entities
- companyModerna
NASDAQ-listed biotech whose valuation and oncology pipeline are central to JPMorgan’s revised target and maintained Underweight stance.
- productintismeran
Moderna’s cancer treatment referenced as the next catalyst via interim Phase II results in adjuvant kidney cancer.
- analyst_firmJPMorgan
Brokerage that raised Moderna’s price target from $77 to $102 while keeping an Underweight rating.




